Literature DB >> 33165563

COVID-19 Hospitalization in Adults with Type 1 Diabetes: Results from the T1D Exchange Multicenter Surveillance Study.

Grenye O'Malley1, Osagie Ebekozien2, Marisa Desimone3, Catherina T Pinnaro4, Alissa Roberts5, Sarit Polsky6, Nudrat Noor2, Grazia Aleppo7, Marina Basina8, Michael Tansey4, Devin Steenkamp9, Francesco Vendrame10, Ilona Lorincz11, Priyanka Mathias12, Shivani Agarwal12, Lauren Golden13, Irl B Hirsch14, Carol J Levy1.   

Abstract

CONTEXT: Diabetes mellitus is associated with increased COVID-19 morbidity and mortality, but there are few data focusing on outcomes in people with type 1 diabetes.
OBJECTIVE: The objective of this study was to analyze characteristics of adults with type 1 diabetes for associations with COVID-19 hospitalization.
DESIGN: An observational multisite cross-sectional study was performed. Diabetes care providers answered a 33-item questionnaire regarding demographics, symptoms, and diabetes- and COVID-19-related care and outcomes. Descriptive statistics were used to describe the study population, and multivariate logistic regression models were used to analyze the relationship between glycated hemoglobin (HbA1c), age, and comorbidities and hospitalization.
SETTING: Cases were submitted from 52 US sites between March and August 2020. PATIENTS OR OTHER PARTICIPANTS: Adults over the age of 19 with type 1 diabetes and confirmed COVID-19 infection were included.
INTERVENTIONS: None. MAIN OUTCOME MEASURES: Hospitalization for COVID-19 infection.
RESULTS: A total of 113 cases were analyzed. Fifty-eight patients were hospitalized, and 5 patients died. Patients who were hospitalized were more likely to be older, to identify as non-Hispanic Black, to use public insurance, or to have hypertension, and less likely to use continuous glucose monitoring or insulin pumps. Median HbA1c was 8.6% (70 mmol/mol) and was positively associated with hospitalization (odds ratio 1.42, 95% confidence interval 1.18-1.76), which persisted after adjustment for age, sex, race, and obesity.
CONCLUSIONS: Baseline glycemic control and access to care are important modifiable risk factors which need to be addressed to optimize care of people with type 1 diabetes during the worldwide COVID-19 pandemic.
© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; adult; hospitalization; type 1 diabetes

Mesh:

Year:  2021        PMID: 33165563      PMCID: PMC7717244          DOI: 10.1210/clinem/dgaa825

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Inequities in Health Outcomes in Children and Adults With Type 1 Diabetes: Data From the T1D Exchange Quality Improvement Collaborative.

Authors:  Shideh Majidi; Osagie Ebekozien; Nudrat Noor; Sarah K Lyons; Ryan McDonough; Kajal Gandhi; Roberto Izquierdo; Carla Demeterco-Berggren; Sarit Polsky; Marina Basina; Marisa Desimone; Inas Thomas; Nicole Rioles; Jose Jimenez-Vega; Faisal S Malik; Brian Miyazaki; Anastasia Albanese-O'Neill; Nana-Hawa Yayah Jones
Journal:  Clin Diabetes       Date:  2021-07

2.  Improved glucometrics in people with type 1 diabetes 1 year into the COVID-19 pandemic.

Authors:  Namam Ali; Soumia El Hamdaoui; Giesje Nefs; Cornelis J Tack; Bastiaan E De Galan
Journal:  BMJ Open Diabetes Res Care       Date:  2022-05

3.  How Do We Move Type 1 Diabetes Immunotherapies Forward During the Current COVID-19 Pandemic?

Authors:  Michael J Haller; Laura M Jacobsen; Amanda L Posgai; Desmond A Schatz
Journal:  Diabetes       Date:  2021-02-25       Impact factor: 9.461

Review 4.  Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin.

Authors:  Clifford J Bailey; Mike Gwilt
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

Review 5.  COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study.

Authors:  Sarra Smati; Blandine Tramunt; Matthieu Wargny; Pierre Gourdy; Samy Hadjadj; Bertrand Cariou
Journal:  Curr Diab Rep       Date:  2022-02       Impact factor: 5.430

6.  Trends in Type 1 Diabetic Ketoacidosis During COVID-19 Surges at 7 US Centers: Highest Burden on non-Hispanic Black Patients.

Authors:  Andrew R Lavik; Osagie Ebekozien; Nudrat Noor; G Todd Alonso; Sarit Polsky; Scott M Blackman; Justin Chen; Sarah D Corathers; Carla Demeterco-Berggren; Mary Pat Gallagher; Margaret Greenfield; Ashley Garrity; Saketh Rompicherla; Robert Rapaport; Nana-Hawa Yayah Jones
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

7.  Achieving Equity in Diabetes Research: Borrowing From the Field of Quality Improvement Using a Practical Framework and Improvement Tools.

Authors:  Osagie Ebekozien; Ann Mungmode; Don Buckingham; Margaret Greenfield; Rashida Talib; Devin Steenkamp; J Sonya Haw; Ori Odugbesan; Michael Harris; Priyanka Mathias; Jane K Dickinson; Shivani Agarwal
Journal:  Diabetes Spectr       Date:  2022-08-15

8.  Intensive Care Unit Admission, Mechanical Ventilation, and Mortality Among Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S.

Authors:  Catherine E Barrett; Joohyun Park; Lyudmyla Kompaniyets; James Baggs; Yiling J Cheng; Ping Zhang; Giuseppina Imperatore; Meda E Pavkov
Journal:  Diabetes Care       Date:  2021-06-22       Impact factor: 17.152

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.